Skip to main content

Real-Time Cell Analysis

xCELLigence Real-Time Cell Analysis

Agilent xCELLigence Real-Time Cell Analysis (RTCA) technology brings you a powerful yet simple tool for live cell analysis. Continuously monitor cell health, behavior, and function through label-free, live-cell impedance and imaging assays.

Non-invasive biosensor technology provides a quantitative readout of cell number, cell morphology, cell substrate attachment quality, and cell barrier function. It enables real-time monitoring of various biological processes, including cell adhesion, cell proliferation, drug-, viral-, and cell-mediated cytotoxicity, stem cell differentiation, cell barrier function formation/disruption, GPCR response, and cell invasion and migration, with minimal hands-on effort.

The xCELLigence RTCA system delivers an objective and highly sensitive kinetic assay that transcends traditional cell morphology analysis, revealing detailed insights into cellular behavior and function.

Real-Time Cell Analysis

Refine By

Products

Featured Literature

Assessing Water Cytotoxicity with an Impedance-Based, Real-Time, and Label-Free Cellular Assay

Noninvasive and continuous monitoring of the perturbation of cellular growth following exposure to the cumulative toxicants present in water samples.

Super Charge Your Cell Research: Agilent Cell Analysis Portfolio

Maximize your workflow efficiency and produce robust data with Agilent solutions in cell analysis.

Enhancing Immune Cell Cytotoxicity and Persistence Insights Using Real-Time Cell Analysis

This editorial will discuss the potency assays available for cellular immunotherapies, the regulatory criteria they must meet, and the challenges faced in measuring immune cell cytotoxicity.

Real-Time Antibody Internalization Assays with Agilent xCELLigence RTCA eSight

This application note demonstrates a robust method for performing real-time antibody internalization assays using the Agilent xCELLigence RTCA eSight combined with CypHer5E pH-sensitive dyes.

Featured Videos
Return to top
Featured News

Agilent xCELLigence RTCA Instrumentation Supports Potency Assay Development in Recent FDA Approval

Agilent xCELLigence Real-Time Cell Analysis (RTCA) technology supports the testing of accuracy and reliability in AUCATZYL, a recently approved CAR T therapy by Autolus Therapeutics. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis capabilities, Agilent supported Autolus's efforts in establishing robust analytical methods.

Agilent Wins Two Scientists’ Choice Awards for Drug Discovery and Development Products

The Agilent xCELLigence RTCA HT-BioTek BioSpa 8 integrates the xCELLigence Real-Time Cell Analyzer (RTCA) HT instrument with the BioTek BioSpa 8 automated incubator to expand the screening throughput of your RTCA HT instrument to eight 384-well plates.

Featured Training & Events

Advancing the Boundaries of Real-Time Live Cell Analysis

Watch our on-demand webinar to explore multiplexed real-time cellular analysis using Agilent xCELLigence RTCA technology.

Webinar/Training

In Vivo DNA-launched Bispecific T Cell Engager Targeting IL-13Ra2 Controls Tumor Growth in an Animal Model of Glioblastoma Multiforme

Immuno-oncology research is changing the landscape of cancer treatment by harnessing the immune system to attack cancer cells. These immunotherapies utilize both the adaptive and innate arms of the immune system, playing a pivotal role in a host’s defense against tumors. Join the Agilent Immuno-Oncology webinar series and learn how experts in the field are making groundbreaking discoveries and taking steps towards a cancer-free world. Glioblastoma is an aggressive tumor with poor survival rates. Bispecific T cell engagers (BTEs) against different cancers are in various stages of clinical development. Toxicity resulting from cytokine release syndrome and the short half-life of BTEs, which necessitates continuous infusion—complicating delivery and increasing costs—are major challenges in the field. Here we describe the development of in vivo DNA-launched BTEs (dBTEs) with highly focused targeting of interleukin-13 receptor a2 (IL-13Ra2), a glioblastoma cell-surface target. We developed 4 BTEs targeting 2 epitopes of IL-13Ra2 and studied how heavy-light chain orientation affects BTE function. The dBTEs induced T cell activation, cytokine production, and tumor cytolysis in the presence of IL-13Ra2+ tumor cells, but we observed unique patterns of immune activation. We found...
Webinar/Training

Accelerating Antibody Therapeutics Development Webinar

Dr. Tsourkas describes how pAbBDs can accelerate the development of antibody-drug conjugates, allows for the exploration of new therapeutic paradigms.
Webinar/Training

Identifying Regulatory Mechanisms in Cancer Metastatic Processes with an Integrated Multi-omics Approach

Identifying Regulatory Mechanisms in Cancer Metastatic Processes with an Integrated Multi-omics Approach
Webinar/Training

0 product selected.

Clear All